Open Access
Table 2
Summary of key studies included in the study.
| Study | Study type | Intervention | Sample size | Findings |
|---|---|---|---|---|
| Anderson et al. [27] | Randomized Controlled Trial | Multicentre, double-blind RCT involving patients who were undergoing THA/TKA. All the patients received once-daily oral rivaroxaban (10 mg) until postoperative day 5 and then were randomly assigned to continue rivaroxaban or switch to aspirin (81 mg daily). | 3424 THA and TKA | Extended prophylaxis with aspirin was not significantly different from rivaroxaban in the prevention of symptomatic venous thromboembolism |
| Anderson et al. [28] | Randomized Controlled Trial | Multicentre randomized, controlled trial with a non-inferiority design. After an initial 10 days of dalteparin prophylaxis after elective THA, patients were randomly assigned to 28 days of dalteparin or aspirin. | 778 THA | Extended prophylaxis for 28 days with aspirin was non-inferior to and as safe as dalteparin for the prevention of VTE |
| Warren et al. [22] | Registry study (National Surgical Quality Improvement Program database) | The American College of Surgeons NSQIP database identified 363,530 patients who received a TKA or THA from 2008 to 2016. Bimodal multivariate logistic regression models for THA and TKA were developed for 2009–2016 using 2008 as a reference. | 363,530 THA and TKA | Overall VTE rate for THA and TKA was 0.6% and 1.4%, respectively within 30 days post-surgery |
| Pedersen et al. [26] | 15-year retrospective cohort study | The risk of thrombotic and major bleeding events in patients undergoing total hip and knee replacement (THR and TKR) treated with thromboprophylaxis, using nationwide population-based databases. | 83,756 THA and TKA | A VTE rate of 1.3% for THA and 1.5% for TKA |
| Fuji et al. [25] | Retrospective analysis of a Japanese healthcare database | The study comprised 36,947 patients who had undergone orthopedic surgeries of the lower extremities, with the source population of the database being derived from 100 acute-care hospitals with diagnosis procedure combination. | 36,947 THA and TKA | An overall VTE rate of 1.4% |
| Wells et al. [33] | A retrospective study | A retrospective study was conducted using a US health plan claims database linked to an in-patient database containing medication use. Outcomes were compared using χ2 tests; predictors of outcomes were analyzed using multivariate logistic regression. | 3497 THA and TKA | Higher VTE rate in patients receiving anticoagulation therapy for less than 14 days (3.9%) compared to more than 14 days (1.4%) |
| Faour et al. [35] | A retrospective study | Exploratory univariate analyses were used to compare confounders between the study groups. Multivariate regression was used to control for confounding variables. | 7488 THA | No difference in the incidence of symptomatic VTE after THA with low-dose (81 mg) compared with standard-dose aspirin (325 mg) |
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.